Smith & Nephew plc Overview
Smith & Nephew plc (SNN) has a ROE of 21.77%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow21.77%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Smith & Nephew plc (SNN) currently reports a ROE of 21.77%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Smith & Nephew plc's ROE history and peer comparisons.
Smith & Nephew plc's ROE of 21.77% is higher than the Healthcare sector average of 11.15%. That is roughly 95.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Smith & Nephew plc's current 21.77% should be judged against Healthcare norms (sector average: 11.15%) and against SNN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 21.77%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Smith & Nephew plc, and consider following SNN for alerts when major investors trade the stock.
Smith & Nephew plc is classified in the Healthcare sector. On ROE, it currently shows 21.77% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SNN with unrelated industries.
